Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised…

Overview of attention for article published in Lancet Oncology, February 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog
twitter: 41 X users

wikipedia: 3 Wikipedia pages
guideline: 2 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 102 Mendeley

So far, Altmetric has seen 1 blog post.

RCT | Temporary cessation vs. continuation of first-line tyrosine kinase inhibitor in advanced clear cell renal cell carcinoma

SPECIALTIES, 22 Feb 2023

Summary: The STAR trial investigated whether a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.